CytoMed Therapeutics (GDTC) currently reports a common stock of $25M as of December 2025. That compares with $17M in the prior-year period — up 41.4% year over year. Use the charts on this page to explore CytoMed Therapeutics's common stock history and peer comparisons.

CytoMed Therapeutics's common stock increased from $17M to $25M — a 41.4% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CytoMed Therapeutics reported $25M in common stock as of December 2025. That compares with $17M in the prior-year period — up 41.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $25M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CytoMed Therapeutics, and consider following GDTC for alerts when major investors trade the stock.